271 results on '"Chen, Shinn-Cherng"'
Search Results
2. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
3. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
4. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan
5. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection
6. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
7. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma
8. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
9. Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
10. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
11. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
12. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
13. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with highNANOGexpression
14. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
15. Tumor Necrosis Factor-α Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection
16. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study
17. Human Leukocyte Antigen Class I and II Alleles and Response to Interferon-α Treatment, in Taiwanese Patients with Chronic Hepatitis C Virus Infection
18. Comparison of Clinical Application of the Abbott HBV PCR Kit and the Versant HBV DNA 3.0 Test to Measure Serum Hepatitis B Virus DNA in Taiwanese Patients
19. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma
20. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
21. Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma
22. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan
23. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
24. Coagulation‐related inflammatory pseudotumor of liver
25. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
26. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
27. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
28. Qualitative Application of COBAS AMPLICOR HCV Test Version 2.0 Assays in Patients with Chronic Hepatitis C Virus Infection and Comparison of Clinical Performance with Version 1.0
29. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C
30. Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
31. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.
32. Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
33. Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
34. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment
35. Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules
36. Tumor necrosis factor-[alpha] promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection
37. Human leukocyte antigen class i and ii alleles and response to interferon-[alpha] treatment, in Taiwanese patients with chronic hepatitis C virus infection. (Brief Report)
38. Alström Syndrome with Acute Pancreatitis: A Case Report
39. Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment.
40. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
41. Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C
42. The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
43. Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus–infected patients
44. Association of hyperuricemia with disease severity in chronic hepatitis C patients
45. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
46. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
47. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
48. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
49. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
50. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.